Assessment of the cardiac safety of prucalopride in healthy volunteers: A randomized, double-blind, placebo- and positive-controlled thorough QT study

British Journal of Clinical Pharmacology

Volumn 73, Issue 2, 2012, Pages 203-209

  Mendzelevski, Boaz ^a   Ausma, Jannie ^b   Chanter, Dennis O ^a   Robinson, Patricia ^b   Kerstens, Rene ^b   Vandeplassche, Lieve ^b   Camm, John ^c  

^a CoreLab Partners Inc ^*  (United Kingdom)

^b Movetis NV   (Belgium)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

5 HT 4; Constipation; Moxifloxacin; Prucalopride; Safety; Study specific QT correction; Thorough QT study

Indexed keywords

MOXIFLOXACIN; PLACEBO; PRUCALOPRIDE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART RATE VARIABILITY; HEART REPOLARIZATION; HOLTER MONITORING; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BENZOFURANS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART RATE; HUMANS; MALE; MIDDLE AGED; SEROTONIN 5-HT4 RECEPTOR AGONISTS; YOUNG ADULT;

EID: 84855513343     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04088.x     Document Type: Article

References (26)

1. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999; 44: 682-86.
2. De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008; 20: 99-112.
3. De Schryver AM, Andriesse GI, Samsom M, Smout AJ, Gooszen HG, Akkermans LM. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002; 16: 603-12.
4. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 2344-54.
5. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29: 315-28.
6. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009; 58: 357-65.
7. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32-45.
8. + channel and the common T897 polymorph. Eur J Pharmacol 2007; 554: 98-105.
9. European Medicines Agency. CHMP assessment report for Resolor (procedure number EMEA/H/C/1012). Document reference EMEA/664892/2009. 2009. Available at: (last accessed 8 September 2011).
10. Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998; 42: 511-16.
11. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 354-60.
12. Krogh K, Jensen MB, Gandrup P, Laurberg S, Nilsson J, Kerstens R, De Pauw M. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 2002; 37: 431-6.
13. Sloots CE, Poen AC, Kerstens R, Stevens M, De Pauw M, Van Oene JC, Meuwissen SG, Felt-Bersma RJ. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002; 16: 759-67.
14. Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003; 67: 82-9.
15. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002; 16: 1347-56.
16. Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009; 21: 1256-e117.
17. European Medicines Agency. ICH Harmonised Tripartite Guideline (E14) (CHMP/ICH/2/04). The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non Antiarrhythmic Drugs. 2005. Available at: (last accessed 8 September 2011).
18. European Medicines Agency. ICH Harmonised Tripartite Guideline (E14) (EMEA/CHMP/ICH/310133/2008). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: questions and answers. 2008. Available at: (last accessed 8 September 2011).
19. Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken [Systolic period in the electrocardiogram in normal humans and in cardiac patients]. Acta Med Scand 1920; 53: 489-506.
20. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 70: 353-70.
21. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, Wagner JA. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 2008; 84: 475-80.
22. Indik JH, Pearson EC, Fried K, Woosley RL. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 2006; 3: 1003-7.
23. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2001; 12: 411-20.
24. Couderc JP, Xiaojuan X, Zareba W, Moss AJ. Assessment of the stability of the individual-based correction of QT interval for heart rate. Ann Noninvasive Electrocardiol 2005; 10: 25-34.
25. Van de Water A, Verheyen J, Xhonneux R, Reneman RS. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 1989; 22: 207-17.
26. Movetis. Summary of product characteristics, Resolor (prucalopride). October, 2009: 1-9.